Tuesday , October 24 2017
Home / Therapies / GLP-1 Agonist Therapy Center (page 10)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Positive Results for Next Once A Week GLP-1

Five studies show positive results for new GLP-1 drug dulaglutide…. Eli Lilly and Company announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Primary efficacy endpoints of ...

Read More »

The Effects of GLP-1 Agonists — A Review of the Drug Class

Amanda Zell, PharmD Candidate, Mercer University College of Pharmacy Glucagon-like peptide-1 (GLP-1) is part of a family of peptide hormones known as incretins. Incretins, such as GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), are secreted by entero-endocrine cells of the gastrointestinal tract to stimulate glucose-dependent insulin secretion and beta-cell proliferation. GLP-1 receptor ...

Read More »

GLP-1 Analogs, Appetite and Satiety

SE-Lifestyle_Art3-1

Cierra Harden PharmD Candidate 2013 LECOM School of Pharmacy, Bradenton Obesity is a major risk factor for the development of diabetes as well as predisposing individuals to hypertension and dyslipidemia. In the United States, 54.8% of persons with diabetes are obese, and 85.2% are overweight or obese1. All of these ...

Read More »